Gildan Activewear Inc. reports US$137.9 million profit for second quarter
MONTREAL — Gildan Activewear Inc. says its earnings rose in the second quarter as it reaffirmed its full-year guidance after considering the impact of tariffs.
The clothing manufacturer, which reports in U.S. dollars, says it earned US$137.9 million in the quarter ending June 29, up from US$58.4 million in the same quarter last year.
The Montreal-based company says its adjusted earnings worked out to US$145.9 million, up from US$124.7 million last year.
It says adjusted earnings were 97 cents per diluted share, up from 74 cents per diluted share last year.
Net sales totalled US$918.5 million in the quarter, up from US$862.2 million in the period last year.
Gildan says in reaffirming its guidance after weighing the impact of tariffs along with the options available to it to mitigate the effects, including pricing and its flexible business model.
This report by The Canadian Press was first published July 31, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Fortinet Stock Before Q2 Earnings: Buy Now or Wait for Results?
Fortinet FTNT is slated to report second-quarter 2025 results on Aug. 6. For the second quarter of 2025, Fortinet expects revenues in the range of $1.59-$1.65 billion. It anticipates non-GAAP earnings per share in the band of 58-60 cents. The Zacks Consensus Estimate for second-quarter revenues is pegged at $1.62 billion, suggesting year-over-year growth of 12.9%. The consensus mark for earnings is pinned at 59 cents per share, which has remained unchanged over the past 30 days. The estimate indicates a year-over-year increase of 3.51%. FTNT Earnings Surprise History In the last reported quarter, the company delivered an earnings surprise of 9.43%. The company's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 23.83%. Fortinet, Inc. Price and EPS Surprise Fortinet, Inc. price-eps-surprise | Fortinet, Inc. Quote Earnings Whispers for DDOG Our proven model does not predict an earnings beat for Fortinet this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. FTNT has an Earnings ESP of 0.00% and carries a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank stocks here. Factors Shaping Upcoming Results of FTNT Fortinet entered the second quarter of 2025 with exceptional momentum following a record-setting first quarter that successfully delivered 14% revenue growth to $1.54 billion and achieved a record operating margin of 34%. The company's strong first-quarter performance was driven by a record free cash flow of $783 million and robust growth in strategic focus areas, with Unified SASE billings increasing 18% and accounting for 25% of total business, while AI-driven secure operations billings surged 29% to represent 10% of the business. During the second quarter, Fortinet launched the highly anticipated FortiGate 700G series, a next-generation firewall that delivered up to 7x higher firewall throughput and 4x better threat protection compared to competitors while consuming 7x less power per gigabit. This innovative product, powered by Fortinet's proprietary Network Processor 7 and Security Processor 5 ASIC technologies, incorporates advanced AI-powered threat detection through FortiAI-Protect and post-quantum cryptography readiness, positioning the company to capture increased market share in the campus security segment. The company further strengthened its comprehensive product portfolio in June with the strategic unveiling of its advanced AI-powered workspace security suite, including FortiMail Workspace Security enhancements and powerful FortiDLP upgrades that extended protection beyond email to include browser and collaboration security. July brought additional validation when Fortinet was recognized as a Leader in the 2025 Gartner Magic Quadrant for SASE Platforms and ranked #1 in the Secure Branch Network Modernization use case. Building on the first-quarter's exceptionally strong new customer acquisition of more than 6,300 new logos representing 14% growth, driven by strategic channel partner investments, and the company's maintained position as the number one deployed firewall vendor worldwide and market leader in SD-WAN and OT security, these highly strategic product launches and significant industry recognition positioned Fortinet for strong second-quarter 2025 financial results and demonstrate continued strong market leadership. While the competitive landscape remains fierce from rivals like Palo Alto Networks PANW, Zscaler ZS and CrowdStrike CRWD, Fortinet's focus on reducing complexity, expanding sales capacity, and accelerating SASE adoption positions it for durable long-term growth, making it a smart buy choice for investors ahead of second-quarter 2025 results. Top-Line Growth Estimates for Q2 Our model estimate for second-quarter 2025 Americas revenues is pegged at $664.8 million, indicating 11.7% growth from the figure reported in the year-ago quarter. Our model estimate for Asia Pacific and Japan revenues is pinned at $324.6 million, indicating growth of 18.6% from the figure reported in the year-ago quarter. Our model estimate for Europe, Middle East and Africa revenues is pegged at $629.5 million, suggesting a 11.4% decrease from the figure reported in the year-ago quarter. Our model estimate for second-quarter 2025 total billings is pegged at $1.73 billion, indicating a 12.3% decrease from the figure reported in the year-ago quarter. FTNT Price Performance & Stock Valuation Shares of Fortinet have gained 4.9% in the year-to-date period, outperforming the Computer and Technology sector and the S&P 500 index's decline of 9.1% and 5.7%, respectively. The company's outperformance can be attributed to its establishment as a leading provider of SASE solutions. SASE adoption is accelerating across enterprises, and to keep pace, Fortinet continuously enhances FortiOS, integrating advanced networking and security into a unified platform. FTNT's YTD Price Performance Fortinet's valuation may be a concern for some investors. The stock is trading at a significant premium compared to the broader Zacks Security industry. As of the latest data, FTNT's Price/Book ratio hovers around 37.97, well above the industry's 17.52, reflecting investors' high growth expectations. The Value Score of F further reinforces a stretched valuation for Fortinet at this moment. FTNT Trades at a Premium Investment Considerations Fortinet represents a compelling investment opportunity despite premium valuation, as the company's record-setting first-quarter performance with 34% operating margins and strategic product launches position it for exceptional second-quarter results. The groundbreaking FortiGate 700G series delivers 7x higher performance and AI-powered security innovations demonstrate sustainable competitive advantages that justify premium pricing. With 18% Unified SASE growth, market-leading positions in firewalls and SD-WAN, and Gartner Magic Quadrant Leadership recognition, Fortinet continues expanding its market share against competitors. Strong customer acquisition exceeding 6,300 new logos and robust free cash flow generation provide a foundation for continued outperformance, making the current valuation attractive before anticipated second-quarter strength. Conclusion Fortinet's exceptional first-quarter momentum, groundbreaking FortiGate 700G launch, and market-leading SASE growth create compelling catalysts for strong second-quarter performance. With record margins, robust customer acquisition, and continued innovation leadership, investors should strategically capitalize on current opportunities before anticipated earnings strength potentially drives significant stock appreciation heading into the August results. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Fortinet, Inc. (FTNT): Free Stock Analysis Report Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report Zscaler, Inc. (ZS): Free Stock Analysis Report CrowdStrike (CRWD): Free Stock Analysis Report
CBC
an hour ago
- CBC
Tariff troubles for home builders
As CBC's Andrea Huncar reports, the trade war with the U.S. is slowing Edmonton's much needed home-building efforts.
Globe and Mail
an hour ago
- Globe and Mail
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, with many large drugmakers like Pfizer PFE, Eli Lilly LLY, Amgen AMGN, Gilead Sciences GILD and Novo Nordisk NVO, among others, due to announce results. The earnings season for the sector kicked off around mid-July when Johnson & Johnson reported solid second-quarter results, beating estimates for both earnings and sales. Novartis and Bristol Myers followed suit, beating second-quarter estimates for both earnings and revenues. Merck beat estimates for earnings while meeting the same for revenues in the second quarter. Meanwhile, AstraZeneca met estimates for earnings while beating the same for revenues in the second quarter. French drugmaker Sanofi came out with disappointing second-quarter results as it missed estimates for both earnings and sales. Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies. Per the Earnings Trends report, as of July 29, 33.3% of the companies in the Medical sector — representing 40.9% of the sector's market capitalization — reported quarterly earnings. Out of these, 80% surpassed earnings estimates, while 95% beat the same for revenues. Earnings declined 10.4% year over year, while revenues rose 11.9%. Overall, second-quarter earnings of the Medical sector are expected to remain flat, while sales are projected to rise 8.7% from the year-ago quarter. Let's see how things have shaped up for these companies ahead of their earnings announcements. Pfizer PFE's performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 43.49%, on average. In the last reported quarter, the company delivered an earnings surprise of 43.75%. The Zacks Consensus Estimate for second-quarter sales and earnings stands at $13.78 billion and 58 cents per share, respectively. Pfizer has an Earnings ESP of +1.43% and a Zacks Rank #3 (Hold), indicating a beat this time around. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Higher sales of Pfizer's products like Vyndaqel family, Padcev, Lorbrena and Nurtec are expected to have offset softer sales of some key products like Prevnar, Xeljanz, Eliquis and Ibrance in the second quarter. The Medicare Part D redesign under the Inflation Reduction Act (IRA) is likely to have impacted U.S. revenues, particularly sales of higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz. PFE is scheduled to report second-quarter results on Aug. 5, before the opening bell. Pfizer Inc. Price and EPS Surprise Eli Lilly LLY's performance has been mixed, with the company exceeding earnings expectations in two of the trailing four quarters and missing the same on the remaining two occasions. It delivered a four-quarter earnings surprise of 6.69%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 5.11%. The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively. LLY has an Earnings ESP of +0.18% and a Zacks Rank #3, indicating a positive earnings surprise this time around. In the second quarter, Lilly's top-line growth is likely to have been driven by its popular GLP-1 drugs, diabetes drug Mounjaro and weight loss medicine, Zepbound, driven by high demand trends. Higher demand and volume growth for Lilly's other key drugs like Emgality, Jardiance, Olumiant, Taltz and Verzenio are likely to have provided top-line support in the second quarter, driven by increased demand trends. LLY is scheduled to report second-quarter results on Aug. 7, before the opening bell. Amgen AMGN's performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 8.34%, on average. In the last reported quarter, the company delivered an earnings surprise of 17.79%. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $8.86 billion and $5.26 per share, respectively. AMGN has an Earnings ESP of +0.56% and a Zacks Rank #3, indicating a positive surprise this time around. Amgen's product sales in the second quarter are likely to have been driven by strong volume growth of products like Evenity, Repatha and Blincyto, among others. However, prices of most products are expected to have declined due to higher rebates to support expanded access. Higher volumes of newer drugs like Tezspire and Tavneos are also expected to have contributed to top-line growth, driven by an increase in new patient volume. AMGN is scheduled to report second-quarter results on Aug. 5, after market close. Gilead Sciences GILD's performance has been mixed, with earnings beating estimates in three of the trailing four quarters and missing the same on the remaining occasion. The company delivered a four-quarter earnings surprise of 16.48%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 0.55%. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $6.95 billion and $1.95 per share, respectively. GILD has an Earnings ESP of +0.58% and a Zacks Rank #3, indicating a positive surprise this time around. Gilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. HIV sales were up in the first quarter despite the impact of the new Medicare Part D model implementation due to increased demand for Biktarvy and Descovy. This trend has most likely prevailed in the second quarter as well. Higher demand for viral hepatitis medicines has likely boosted sales of the Liver Disease portfolio in the second quarter. GILD is scheduled to report second-quarter results on Aug. 7, after market close. Novo Nordisk NVO's performance has been mixed, with earnings beating estimates in one of the trailing four quarters, meeting the same once and missing the same on the remaining two occasions. The company delivered a four-quarter earnings surprise of 0.02%, on average. In the last reported quarter, the company delivered in-line earnings. The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $11.79 billion and 93 cents per share, respectively. NVO has an Earnings ESP of +0.22% and a Zacks Rank #4 (Sell). Last week, NVO lowered its 2025 outlook for both sales and operating profit growth. The company expects sales to rise 8-14% in 2025, down from its earlier forecast of 13-21%. Similarly, it revised its operating profit growth projection to 10-16%, down from the prior range of 16-24%. NVO cited weaker-than-expected momentum in key markets for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, as reasons for the guidance cut. Also, during the same time, Novo Nordisk reported preliminary earnings per American Depositary Receipt of 91 cents (DKK 5.96), which missed the Zacks Consensus Estimate of 94 cents. The company said its sales for the second quarter have increased 18% at a constant exchange rate. Novo Nordisk is set to release results on Aug. 6, before the opening bell. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
